Previous 10 | Next 10 |
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its in...
NEW YORK, NY / ACCESSWIRE / August 18, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against 1Globe Capital LLC ("1Globe") on behalf of a class consisting of all holders of Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:...
Securities Litigation Partner James (Josh) Wilson Notifies Sinovac Biotech Ltd. (SVA) Investors of Class Action Against 1Globe Capital LLC To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - August 17, 2022) - Faruqi & Faruqi, LLP, a leading national sec...
Sinovac Biotech ( NASDAQ: SVA ) on Wednesday said its COVID-19 vaccine had been given approval for use in children aged six months to three years in Hong Kong. The Health Bureau of the Government of the Hong Kong Special Administrative Region of the People's Republic of Ch...
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the...
Sinovac Biotech ( NASDAQ: SVA ) said a phase 3 trial of its quadrivalent influenza vaccine was started in the Republic of Chile in collaboration with Pontificia Universidad Católica de Chile (PI Dr. Pablo González). The study will evaluate the vaccine am...
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine was initiated in the Republic...
Sinovac Biotech ( NASDAQ: SVA ) said its COVID-19 vaccine CoronaVac was approved by the Brazilian Health Regulatory Agency (Anvisa) for emergency use in children three to five years old, on July 13. The Chinese company said the children will receive the same dose that ...
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine (CoronaVac) has been approved by the Brazilian Health Regulatory Agency (Anvisa) for emergency use ...
Clover Biopharmaceuticals said that a third dose of its COVID-19 vaccine showed neutralizing antibody levels against Omicron variants in a trial. Clover noted that it created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax Technologies (NASDAQ:DVAX) CpG 1018 advanc...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerativ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual r...
--News Direct-- Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 –...